Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN No change' for CagriSema as Novo ditches single chamber device Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Novo Nordisk Offers New Contender in Weight Management Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination